Cover Image
市場調查報告書

Acadia Pharmaceuticals Inc.的產品平台分析

Acadia Pharmaceuticals Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 240905
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Acadia Pharmaceuticals Inc.的產品平台分析 Acadia Pharmaceuticals Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 39 Pages
簡介

Acadia Pharmaceuticals Inc. (舊 Receptor Technologies, Inc.)是主要開發、銷售思覺失調症和老年癡呆症等中樞神經系統障礙治療的小分子藥物的生物製藥公司。

本報告提供Acadia Pharmaceuticals Inc.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的/作用機製/給藥途徑/分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Acadia Pharmaceuticals Inc.的基本資料

  • Acadia Pharmaceuticals Inc.概要
  • 主要資訊
  • 企業資料

Acadia Pharmaceuticals Inc.:R&D概要

  • 主要的治療範圍

Acadia Pharmaceuticals Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Acadia Pharmaceuticals Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Acadia Pharmaceuticals Inc.:藥物簡介

  • pimavanserin tartrate
  • AGN-XX/YY
  • AC-262271
  • AC-186
  • OSU-6162
  • 神經學及疼痛用雌激素受體β活化小分子
  • 帕金森氏症的Nurr-1/RXR活化小分子

Acadia Pharmaceuticals Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Acadia Pharmaceuticals Inc.:最近的開發平台趨勢

Acadia Pharmaceuticals Inc.:暫停中的計劃

Acadia Pharmaceuticals Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • AM-831

Acadia Pharmaceuticals Inc.:企業發表

Acadia Pharmaceuticals Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07213CDB

Summary

Global Markets Direct's, 'Acadia Pharmaceuticals Inc. - Product Pipeline Review - 2015', provides an overview of the Acadia Pharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acadia Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Acadia Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Acadia Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Acadia Pharmaceuticals Inc.'s pipeline products

Reasons to buy

  • Evaluate Acadia Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Acadia Pharmaceuticals Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Acadia Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Acadia Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acadia Pharmaceuticals Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Acadia Pharmaceuticals Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Acadia Pharmaceuticals Inc. Snapshot
    • Acadia Pharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Acadia Pharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Acadia Pharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Acadia Pharmaceuticals Inc. - Pipeline Products Glance
    • Acadia Pharmaceuticals Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Acadia Pharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Acadia Pharmaceuticals Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Acadia Pharmaceuticals Inc. - Drug Profiles
    • pimavanserin tartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-XX/YY
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-262271
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-186
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OSU-6162
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule Agonizing ER-Beta for Neurology and Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Nurr-1 RXR for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acadia Pharmaceuticals Inc. - Pipeline Analysis
    • Acadia Pharmaceuticals Inc. - Pipeline Products by Target
    • Acadia Pharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Acadia Pharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Acadia Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action
  • Acadia Pharmaceuticals Inc. - Recent Pipeline Updates
  • Acadia Pharmaceuticals Inc. - Dormant Projects
  • Acadia Pharmaceuticals Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AM-831
  • Acadia Pharmaceuticals Inc. - Company Statement
  • Acadia Pharmaceuticals Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Acadia Pharmaceuticals Inc., Key Information
  • Acadia Pharmaceuticals Inc., Key Facts
  • Acadia Pharmaceuticals Inc. - Pipeline by Indication, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Acadia Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Acadia Pharmaceuticals Inc. - Out-Licensed Products in Pipeline, 2015
  • Acadia Pharmaceuticals Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Acadia Pharmaceuticals Inc. - Phase III, 2015
  • Acadia Pharmaceuticals Inc. - Phase II, 2015
  • Acadia Pharmaceuticals Inc. - Phase I, 2015
  • Acadia Pharmaceuticals Inc. - Preclinical, 2015
  • Acadia Pharmaceuticals Inc. - Discovery, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Target, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Route of Administration, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Molecule Type, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2015
  • Acadia Pharmaceuticals Inc. - Recent Pipeline Updates, 2015
  • Acadia Pharmaceuticals Inc. - Dormant Developmental Projects,2015
  • Acadia Pharmaceuticals Inc. - Discontinued Pipeline Products, 2015
  • Acadia Pharmaceuticals Inc., Subsidiaries

List of Figures

  • Acadia Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Acadia Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Acadia Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top